RT Journal Article
SR Electronic
T1 Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.23.20160317
DO 10.1101/2020.07.23.20160317
A1 Hu, Shixiong
A1 Wang, Wei
A1 Wang, Yan
A1 Litvinova, Maria
A1 Luo, Kaiwei
A1 Ren, Lingshuang
A1 Sun, Qianlai
A1 Chen, Xinghui
A1 Zeng, Ge
A1 Li, Jing
A1 Liang, Lu
A1 Deng, Zhihong
A1 Zheng, Wen
A1 Li, Mei
A1 Yang, Hao
A1 Guo, Jinxin
A1 Wang, Kai
A1 Chen, Xinhua
A1 Liu, Ziyan
A1 Yan, Han
A1 Shi, Huilin
A1 Chen, Zhiyuan
A1 Zhou, Yonghong
A1 Sun, Kaiyuan
A1 Vespignani, Alessandro
A1 Viboud, Cécile
A1 Gao, Lidong
A1 Ajelli, Marco
A1 Yu, Hongjie
YR 2020
UL http://medrxiv.org/content/early/2020/11/03/2020.07.23.20160317.abstract
AB Several mechanisms driving SARS-CoV-2 transmission remain unclear. Based on individual records of 1,178 SARS-CoV-2 infectors and their 15,648 contacts in Hunan, China, we estimated key transmission parameters. The mean generation time was estimated to be 5.7 (median: 5.5, IQR: 4.5, 6.8) days, with infectiousness peaking 1.8 days before symptom onset, with 95% of transmission events occurring between 8.8 days before and 9.5 days after symptom onset. Most of transmission events occurred during the pre-symptomatic phase (59.2%). SARS-CoV-2 susceptibility to infection increases with age, while transmissibility is not significantly different between age groups and between symptomatic and asymptomatic individuals. Contacts in households and exposure to first-generation cases are associated with higher odds of transmission. Our findings support the hypothesis that children can effectively transmit SARS-CoV-2 and highlight how pre-symptomatic and asymptomatic transmission can hinder control efforts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Science Fund for Distinguished Young Scholars (No. 81525023), National Science and Technology Major Project of China (No. 2017ZX10103009-005, No. 2018ZX10713001-007, No. 2018ZX10201001-010), and Hunan Provincial Innovative Construction Special Fund: Emergency response to COVID-19 outbreak (No. 2020SK3012).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethic committee of the Hunan CDC with a waiver of informed consent due to a public health outbreak investigation (IRB No. 2020005).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual-based data on 1,178 SARS-CoV-2 infected individuals and their 15,648 contacts identified by contact tracing monitoring over the period from January 13-April 02, 2020 were extracted from the notifiable infectious diseases reporting system in Hunan Province, China. Demographic characteristics, severity classification, exposure and travel history, and key clinical timelines were retrieved.All relevant data are within the manuscript and its Supporting Information files.